J&J's treatment for depression succeeds in late stage study-March 2024-www.financetom.com

J&J's treatment for depression succeeds in late stage study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

J&J's treatment for depression succeeds in late stage study

May 29, 2024 6:17 AM

May 29 (Reuters) - Johnson & Johnson ( JNJ ) said on

Wednesday its experimental therapy, seltorexant, met all main

and secondary goals in a late-stage study evaluating it in

patients with major depressive disorder (MDD) and insomnia

symptoms.

The therapy was given as a supplemental treatment to

antidepressants in the study.

Previous page： DiaMedica Therapeutics Files $100 Million Mixed Shelf Next page： Allegiant Travel Reaches Tentative 5-Year Agreement with Union on Flight Attendants Wages

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

DiaMedica Therapeutics Files $100 Million Mixed Shelf

Mar 21, 2024

05:51 PM EDT, 03/21/2024 (MT Newswires) -- DiaMedica Therapeutics ( DMAC ) on Thursday filed a registration statement with the US Securities and Exchange Commission for the potential sale of up to $100 million of its securities from time to time in one or more offerings. The filing covers common shares, warrants and units. The company said it intends to...

Allegiant Travel Reaches Tentative 5-Year Agreement with Union on Flight Attendants Wages

Mar 21, 2024

05:45 PM EDT, 03/21/2024 (MT Newswires) -- Allegiant Travel ( ALGT ) reached a tentative agreement with Transport Workers Union Local 577 regarding a five-year contract on flight attendants' wages, the union said Thursday. The tentative agreement includes an average wages increase of 25% with flight attendants at the higher end of the wage scale getting a 41% increment if...

Intrepid Potash Insider Sold Shares Worth $661,531, According to a Recent SEC Filing

Mar 21, 2024

05:56 PM EDT, 03/21/2024 (MT Newswires) -- Robert P Jornayvaz III, 10% Owner, Director, Executive Chairman & CEO, on March 19, 2024, sold 33,868 shares in Intrepid Potash ( IPI ) for $661,531. Following the Form 4 filing with the SEC, Jornayvaz has control over a total of 1,999,310 shares of the company, with 508,874 shares held directly and 1,490,436...

Algonquin Power Shareholder Starboard Nominates 3 Candidates to Board

Mar 21, 2024

05:55 PM EDT, 03/21/2024 (MT Newswires) -- Algonquin Power & Utilities ( AQNB ) shareholder Starboard Value said late Thursday it has nominated three candidates for election to the company's board at its annual shareholder meeting, scheduled for June 4. Starboard said it holds a roughly 9% stake in Algonquin, making it the company's largest shareholder. Its director nominees are...